Relation between 3435C>T multidrug resistance 1 gene polymorphism with high dose methylprednisolone treatment of childhood acute idiopathic thrombocytopenic purpura

Gene

Volumn 487, Issue 1, 2011, Pages 80-83

  Akin, Mehmet ^a   Turgut, Sebahat ^b   Ayada, Ceylan ^b   Polat, Yusuf ^a   Balci, Yasemin Isik ^b   Erdoǧan, Firat ^c  

^a DENIZLI STATE HOSPITAL   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

^c ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

Author keywords

High dose methylprednisolone; Idiopathic thrombocytopenic purpura; MDR1

Indexed keywords

METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; DRUG MEGADOSE; EXON; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; IDIOPATHIC DISEASE; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ACUTE DISEASE; ALLELES; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE FREQUENCY; GENOTYPE; GLUCOCORTICOIDS; HUMANS; MALE; METHYLPREDNISOLONE; P-GLYCOPROTEIN; PLATELET COUNT; POLYMORPHISM, SINGLE NUCLEOTIDE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

EID: 80052338013     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.06.019     Document Type: Article

References (20)

1. Akbayram S., et al. The clinical outcome of 260 pediatric ITP patients in one center. Clin Appl Thromb Hemost 2010, Aug 16. [Epub ahead of print].
2. Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med. 2002, 346:995-1008.
3. Demircioglu F., et al. Clinical features, treatment responses, and outcome of children with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 2009, 26:526-532.
4. Drozdzik M., et al. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol. 2006, 62:933-937.
5. Hoffmeyer S., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97:3473-3478.
6. Kalyoncu D., Yildirmak Y., Cetinkaya F. Comparison of idiopathic thrombocytopenic purpura in children between 3months and 2years versus 2-5years. Pediatr. Blood Cancer 2009, 52:656-658.
7. Klimecki W.T., et al. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994, 83:2451-2458.
8. Kühne T., et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003, 43:605-608.
9. Levy A.S., et al. High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br J Haematol. 2002, 118:836-838.
10. Llorente L., et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders I. Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000, 67:30-39.
11. López-Karpovitch X., Graue G., Crespo-Solís E., Piedras J. Multidrug resistance-1 in T lymphocytes and natural killer cells of adults with idiopathic thrombocytopenic purpura: effect of prednisone treatment. Arch. Med. Res. 2008, 39:541-545.
12. Lum B.L., Gosland M.P. MDR expression in normal tissues: pharmacological implications for the clinical use of the P-glycoprotein inhibitors. Hematol. Oncol. Clin. North Am. 1995, 9:319-336.
13. Ozer E.A., et al. Oral cyclic megadose methylprednisolone therapy for chronic immune thrombocytopenic purpura in childhood. Eur J Hematol. 2000, 64:411-415.
14. Rodeghiero F., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009, 113:2386-2393.
15. Sutor A.H., Harms A., Kaufmehl K. Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany. Semin. Thromb. Hemost. 2001, 27:253-267.
16. Turgut S., Turgut G., Atalay E.O. Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey. Mol. Biol. Rep. 2006, 33:295-300.
17. Wang D., et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005, 15:693-704.
18. Watts R.G. Immune thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of Alabama. Clin. Pediatr. 2004, 43:691-702.
19. Yaprak I., et al. Variant clinical courses in children with immune thrombocytopenic purpura: sixteen year experience of a single medical center. Turk J Hematol. 2010, 27:147-155.
20. Zhenfeng Duan, Brakora Katherine A., Seiden Michael V. MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. Gene 2004, 340:53-59.